Description

Liver cancer is one of the most fatal cancers in Europe, yet early diagnosis remains a major challenge in primary care. In this episode, features Helen Jarvis, NIHR GP Academic Clinical Lecturer, to explore the barriers preventing timely detection and potential policy recommendations. With liver cancer cases projected to rise by 22% by 2040 in the European region, addressing these obstacles has never been more urgent.

The EASL Policy Dialogues Season 4 is supported by Novo Nordisk. EASL has received no input from Novo Nordisk with regards to the content of the EASL Policy Dialogues Season 4.

Speaker

 
HJ

Helen Jarvis, NIHR GP Academic Clinical Lecturer, Population and Health Sciences Institute, Newcastle University

Dr. Helen Jarvis is a general medical practitioner (GP) with a specialist interest in liver disease. She is researching the development of primary care pathways to better detect and manage liver disease in the community as part of a National Institute of Health Research (NIHR) academic clinical lectureship. She has a particular interest in liver disease as part of the wider management of cardiometabolic risk and pathway implementation challenges in the primary care setting.

Dr. Jarvis is also co-lead on an NIHR applied research collaborative (ARC) funded study researching the implementation of clinical decision support tools to aid early detection of viral hepatitis and HIV in the primary care setting, and a primary care co-investigator on a regional cohort study to develop the optimum non-invasive testing strategy for the early detection of chronic liver disease in primary care.

She sits as the primary care lead on the UK Liver Alliance (and formerly the UK Lancet Liver Commission), is a clinical advisor and college rep for the Royal College of General Practitioners (RCGP) and is a clinical advisor to the British Liver Trust - the largest liver disease charity in the UK

 

Log in to post comments